Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

NCT00356811 ·Status: COMPLETED ·Phase: PHASE2

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

NCT03709082 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial

NCT06857305 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3

A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma

NCT00369512 ·Status: COMPLETED ·Phase: PHASE2

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

NCT03803761 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2

NCT03908749 ·Status: UNKNOWN

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

NCT02040857 ·Status: COMPLETED ·Phase: PHASE2

Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00079053 ·Status: COMPLETED ·Phase: PHASE1

A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer

NCT02053636 ·Status: COMPLETED ·Phase: PHASE2

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

NCT06756932 ·Status: RECRUITING ·Phase: PHASE1

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NCT07054190 ·Status: RECRUITING ·Phase: PHASE2

Irinotecan for Advanced and Metastatic Breast Cancer

NCT03562390 ·Status: UNKNOWN ·Phase: PHASE2

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

NCT05455619 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

NCT03238196 ·Status: COMPLETED ·Phase: PHASE1

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

NCT05508906 ·Status: RECRUITING ·Phase: PHASE1

Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.

NCT04053322 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

NCT03455270 ·Status: COMPLETED ·Phase: PHASE1

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

NCT02037529 ·Status: SUSPENDED ·Phase: PHASE3

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

NCT03471663 ·Status: COMPLETED ·Phase: PHASE1

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

NCT03772353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

NCT06439771 ·Status: RECRUITING ·Phase: PHASE2

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

NCT03099174 ·Status: COMPLETED ·Phase: PHASE1

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

NCT04394247 ·Status: COMPLETED

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

NCT00680758 ·Status: COMPLETED ·Phase: PHASE1

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

NCT06105632 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2